Market News & Trends
MilliporeSigma Opens $350 Million Bioprocessing Facility in South Korea
MilliporeSigma has opened a new bioprocessing production center in Daejeon, South Korea, following an investment of more than $350 million, expanding regional capacity for biologics manufacturing materials.
Frost & Sullivan Report Tracks China's Expanding Role in Global Biopharmaceutical Development
A new Frost & Sullivan report examines how China’s biopharmaceutical industry is moving beyond traditional manufacturing to compete globally through innovative medicines, licensing agreements, and technology partnerships.
Biologics Contract Manufacturing Market Projected to Reach $110B by 2035
The global biologics contract manufacturing market is projected to reach $110.05 billion by 2035, growing at a 14% CAGR as drug developers turn to CDMOs for capacity and specialized expertise.
Lonza Expands Bioconjugation Capacity to Support ADC Manufacturing From Clinical Development to Commercial Supply
Lonza is expanding bioconjugation manufacturing at its Visp, Switzerland, site, upgrading mid-scale suites to 500-liter single-use capacity by 2027 and building a new large-scale facility for 2028. The expansion supports antibody-drug conjugates and other bioconjugated medicines from clinical development through commercial supply.
Adial Pharmaceuticals Rebrands as Azora Therapeutics Ahead of Planned Clinical Trial
Adial Pharmaceuticals has rebranded as Azora Therapeutics, with Matt Davidson as president and CEO, as it prepares a Phase 1 trial of AT177 for ulcerative colitis in the first half of 2027.
FDA Proposes Streamlined Approval Pathway for Personalized Gene Therapies as CMS Expands Medicaid Access Initiative
The FDA has issued draft guidance that would let multiple patient-specific gene therapy versions share a single biologics license application, while CMS plans to expand its Cell and Gene Therapy Access Model beyond sickle cell disease.
Vertex Pharmaceuticals Plans New Research Facility at Harwell Science Campus
Vertex Pharmaceuticals plans a 155,000-square-foot research facility at the Harwell Science and Innovation Campus in Oxfordshire, with construction expected to begin in early 2027.
Codis Advances Haverhill Expansion to Increase Commercial Spray Drying Capacity
Codis has completed demolition at its Haverhill, U.K., site, clearing the way for a new GEA spray dryer that will expand commercial-scale production of amorphous solid dispersions, with capacity expected in the fourth quarter of 2027.
Humanitas Global Health Secures LSU AI Technology License to Advance Drug Discovery and Medication Safety
Humanitas Global Health has launched to commercialize LSU’s DeepDrug AI technologies for drug discovery and medication safety. The company is also developing InteractIQ, an AI platform designed to identify potentially harmful drug-drug interactions.
Adalvo Acquires Romiplostim Biosimilar Program to Expand Biologics Portfolio
Adalvo has acquired a romiplostim biosimilar program from Enzene, adding a complex biologic candidate referencing Nplate to its growing portfolio. Enzene will continue development and manufacturing at its GMP facilities in Pune, India, supporting regulatory submissions worldwide.
ISR Market Research Develops AI-Powered Platform for Pharma Outsourcing Intelligence
ISR Market Research is developing an AI-enabled platform to help pharmaceutical and biotechnology companies access market intelligence and make more informed outsourcing decisions, with launch targeted for early 2027.
Aptar Pharma Acquires Pulmotree to Advance Next-Generation Inhaled Drug Delivery
Aptar Pharma has acquired Pulmotree, adding the Kolibri non-propellant liquid inhaler platform to its respiratory portfolio. The deal builds on the companies’ 2024 collaboration and aims to accelerate inhaled therapies, including complex biologics, toward commercialization.
FDA Grants Breakthrough Status to Sumitomo Pharma's Investigational Leukemia Drug Enzomenib
The FDA has granted Breakthrough Therapy designation to Sumitomo Pharma America’s investigational drug enzomenib for patients with relapsed or refractory acute leukemia characterized by KMT2A rearrangements.
Pathos AI Partners With Bristol Myers Squibb and Tempus to Apply AI to Alzheimer's Drug Development
Pathos AI is partnering with Bristol Myers Squibb and Tempus AI to use artificial intelligence and large-scale patient data to advance drug development for Alzheimer’s disease and other neurological conditions.
Aptar Pharma and Stevanato Group Team Up to Streamline Prefilled Syringe Development
Aptar Pharma and Stevanato Group are collaborating to help drug developers evaluate prefilled syringe systems earlier, combining glass syringe platforms with elastomeric components to generate assembled-system performance data.
ABIONYX Pharma Completes CER-001 Manufacturing Network With AXPLORA Partnership
ABIONYX Pharma has finalized the manufacturing network for CER-001 through a partnership with AXPLORA, completing the production chain for its investigational biologic for LCAT deficiency and sepsis.
Gilead to Acquire PepStar's Oral Inflammation Drug Program in $1.275B Deal
Gilead Sciences has agreed to acquire PepStar Therapeutics’ investigational oral IL-23R drug program HCXT-2001 for $1.275 billion in cash, expanding its pipeline for chronic inflammatory diseases. The deal is expected to close in the fourth quarter of 2026.
AAPS PharmSci 360 Spotlights AI and Adaptive Approaches to Drug Development
AAPS PharmSci 360 2026 opened in New Orleans with a plenary on AI, adaptive clinical trials, and novel alternative methods reshaping how medicines are developed.
AstraZeneca Reports Survival Benefit for Experimental ADC in Advanced Stomach Cancer Trial
AstraZeneca’s investigational ADC sonesitatug vedotin extended median overall survival to 10 months versus five months with chemotherapy in advanced gastric cancer, though the Phase III trial missed its progression-free survival endpoint.
OpenAI Acquires Orchestra Bio to Connect AI Research With Drug Development Workflows
OpenAI has acquired Orchestra Bio, bringing its drug-development program coordination platform into the Rosalind life sciences initiative to connect AI-driven scientific reasoning with the operational work of advancing drug candidates.
